The Latest Breaking News from Pfizer

It's not known how long the vaccines will offer protection for, experts have admitted

In the U.S., officials have asked vaccine makers to target BA.5, rather than the original omicron strain. That has delayed the boosters' development — but officials hope they will be more effective.

The autumn booster program for Covid vaccinations will begin shortly. Over 50s, carers, frontline health workers and those at clinical risk will be inited to get a booster jab.

The groundbreaking Moderna jabs, which target both the Omicron variant and the original strain of the killer virus, will be rolled out in a bid to avoid a winter NHS nightmare

Pfizer (NYSE:PFE) announced positive top-line results from its pivotal U.S. Phase 3 study in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD). The study met two co-primary objectives, associated with immunogenicity responses. Pfizer shares traded in a range of $48.55 to…

Sanofi SA (NASDAQ: SNY), GSK Plc (NYSE: GSK), and Haleon Plc (NYSE: HLN) have lost a combined $40 billion in mar

There are several ways you can book an appointments for yours

There isn't currently a Lyme disease vaccine on the U.S. market. Researchers are hoping to change that.

Here's a roundup of top developments in the biotech space over the last 24 hours: